Proteomics International secures Australian patent notice of acceptance for endometriosis innovative diagnostic test
IP Australia has provided a notice of acceptance for a patent protecting the PromarkerEndoproprietary blood test for the diagnosis of endometriosis
Major milestone with patent granted in PIQs local healthcare market
The patent supports commercialisation efforts and underpins the commercialisation pathway,enabling future partnerships and licensing opportunities.
Published clinical data has demonstrated the patented blood test has high accuracy fordiagnosing endometriosis, including in the early stages of the disease
Patent protection for the PromarkerEndo technology has now advanced in major jurisdictionsincluding Japan, the United States and Australia
Global need - endometriosis affects one in nine women and currently diagnosis typically takes anaverage of 7 years
View ASX Announcement: here